Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. (Q43586612)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

1 reference

1 reference

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1

Sulkowski MS

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Wasserman R

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Brooks L

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Ball L

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

1 May 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

243-250

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15117326%20AND%20SRC:MED&resulttype=core&format=json

Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X

A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00490.X